Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07090499 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

A Phase 1 study of Head and Neck Cancer and Bladder Cancer, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
310
Enrollment target
20
Study locations

NCT07090499 is a Phase 1 study of Head and Neck Cancer and Bladder Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 310 participants, above the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07090499, a Phase 1 study of Head and Neck Cancer and Bladder Cancer, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
310 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Conditions Studied

Head and Neck Cancer Bladder Cancer Carcinoma, Non-Small Cell Lung Esophageal Cancer Urothelial Carcinoma Gastroesophageal Junction Adenocarcinoma Esophageal Squamous Cell Carcinoma Advanced Non-Small-Cell Lung Cancer Carcinoma, Squamous Cell of Head and Neck Advanced/Metastatic Solid Tumors

Interventions

  • DRUG PF-08046876

Study Locations (20)

California

  • City of Hope National Medical Center - Duarte
  • City of Hope at Irvine Lennar - Irvine
  • Ronald Reagan UCLA Medical Center - Los Angeles
  • UCLA Department of Medicine-Hematology/Oncology - Los Angeles
  • Santa Monica UCLA Medical Center & Orthopaedic Hospital - Santa Monica
  • UCLA Hematology/Oncology - Santa Monica - Santa Monica

Texas

  • The University of Texas MD Anderson Cancer Center - Conroe - Conroe
  • University of Texas MD Anderson Cancer Center - Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston - Houston
  • The University of Texas, MD Anderson Cancer Center - League City - League City
  • NEXT Oncology - San Antonio

Connecticut

  • Smilow Cancer Hospital - Yale New Haven Health - New Haven
  • Yale - New Haven Hospital - Yale Cancer Center - New Haven
  • Smilow Cancer Hospital Phase 1 Unit - New Haven
  • Smilow Cancer Hospital - Trumbull - Trumbull

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana-Farber Cancer Institute - Boston
  • Dana-Farber Cancer Institute - Chestnut Hill - Newton

Tennessee

  • Sarah Cannon Research Institute - Pharmacy - Nashville
  • SCRI Oncology Partners - Nashville

Trial Details

FieldValue
Enrollment Target 310 participants
Start Date 2025-08-20
Est. Completion 2029-07-08
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07090499

The ClinicalTrials.gov registry entry for NCT07090499 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (19% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which PF-08046876 is the first listed.

NCT07090499 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Texas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT07090499 about?

NCT07090499 is a clinical study titled "A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors". The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs ...

What is the current status of trial NCT07090499?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 310 participants. The study started on 2025-08-20. Estimated completion is 2029-07-08.

What conditions does trial NCT07090499 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Bladder Cancer, Carcinoma, Non-Small Cell Lung, Esophageal Cancer, Urothelial Carcinoma.

What interventions are being tested in trial NCT07090499?

The interventions under investigation include: PF-08046876 (DRUG).

Who is sponsoring clinical trial NCT07090499?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07090499 being conducted?

This trial has 20 study locations across California, Connecticut, Massachusetts, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Bladder Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.